A detailed history of Capital Performance Advisors LLP transactions in Xencor Inc stock. As of the latest transaction made, Capital Performance Advisors LLP holds 3 shares of XNCR stock, worth $75. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3
Holding current value
$75
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$15.7 - $21.65 $47 - $64
3 New
3 $0

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.51B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.